Sesame Care review: the only brand-name path

In a telehealth market crowded with compounded semaglutide, sublingual drops, and creative pharmaceutical marketing, Sesame Care is an unusual case: they do the simple, straightforward thing. A clinician sees you on telehealth, prescribes an FDA-approved medication, and your prescription is filled through a real pharmacy at manufacturer-direct pricing. No compounded products. No "oral tirzepatide" drops. No guarantee that relies on fine print.

For patients who specifically want the FDA-approved Wegovy pill (oral semaglutide 25 mg) or Rybelsus (oral semaglutide 14 mg), Sesame Care is the most compliant telehealth platform we've reviewed. This review focuses on their oral GLP-1 pathway specifically.

What makes Sesame different

Most GLP-1 telehealth companies built their business on a combination of branded drugs (when they could get them) and compounded alternatives (which are higher margin and don't require manufacturer approval). Sesame took the opposite approach: they operate as a brand-only platform and earned official recognition from Novo Nordisk as a Novo Nordisk Recognized Care Provider.

That designation means three things in practice:

1. Sesame's clinicians can prescribe Novo Nordisk's oral GLP-1 medications (Wegovy pill, Rybelsus) through standard retail and mail-order pharmacy channels
2. Qualifying patients can access NovoCare Direct pricing — the $149/month self-pay rate for starter doses of the Wegovy pill
3. Sesame does not offer compounded semaglutide or tirzepatide anywhere in the program

The recognition doesn't mean Sesame is owned by or controlled by Novo Nordisk — it's an arm's-length provider recognition, not a subsidiary relationship. But it does mean Sesame operates within Novo Nordisk's approved framework for prescribing and dispensing, which gives the company a regulatory posture that compounding platforms can't match.

The $149/month Wegovy pill pricing, explained

When Novo Nordisk launched the 25 mg oral Wegovy tablet in January 2026, they simultaneously launched NovoCare Direct — a manufacturer-direct pricing program that offers specific doses of branded GLP-1 medications to cash-paying patients at substantially reduced rates. The Wegovy pill starter dose (1.5 mg) is priced at $149/month through the program. Maintenance doses (9 mg and 25 mg) are priced at $299/month.

Sesame Care is one of the primary telehealth pathways to this pricing. Here's how it works in practice:

1. You complete an intake with a Sesame clinician (telehealth visit, typically 15–30 minutes)
2. If medically appropriate, the clinician writes a prescription for the Wegovy pill
3. Sesame routes the prescription to a partner pharmacy that fills at NovoCare Direct pricing
4. You pay Sesame a telehealth fee (separate from the medication cost) and the pharmacy charges the $149 (starter) or $299 (maintenance)
5. Follow-up visits are scheduled for dose escalation and monitoring

Wegovy pill vs Rybelsus through Sesame

Sesame can prescribe either oral semaglutide product, depending on your medical picture:

Wegovy pill (25 mg oral semaglutide)

The appropriate choice for most patients seeking oral GLP-1 for weight loss. Obesity-indicated. Maximum dose is 25 mg daily, which produced ~13.6% mean weight loss at 64 weeks in the OASIS 4 trial. Priced at $149/month starter, $299/month maintenance through NovoCare Direct.

Rybelsus (14 mg oral semaglutide)

FDA-indicated for type 2 diabetes. Often the right choice if you have diabetes and are seeking both glucose management and weight-loss benefits. Commercial insurance is more likely to cover Rybelsus than the Wegovy pill because of the diabetes indication. Cash-pay pricing without insurance is substantially higher than the Wegovy pill ($900–$1,400/month at retail), so Rybelsus through Sesame typically only makes financial sense with insurance coverage.

The clinical distinction your Sesame prescriber will weigh: Rybelsus's 14 mg dose caps at roughly half the obesity-indicated Wegovy pill dose, and trial data show substantially less weight loss at that dose. For pure weight-loss goals without diabetes, the Wegovy pill is the stronger choice.

Insurance coverage: the honest picture

Insurance coverage for oral GLP-1 medications in 2026 is complicated and depends heavily on your specific plan:

• Wegovy pill (obesity indication): Coverage is still limited as the drug is new. Some commercial plans cover it with prior authorization and documented obesity (BMI ≥30, or ≥27 with comorbidity). Medicare does not cover weight-loss medications as a category. Medicaid coverage varies by state.
• Rybelsus (diabetes indication): Coverage is substantially broader because the indication is type 2 diabetes. Most commercial plans cover Rybelsus with standard prior authorization, and Medicare Part D plans typically cover it as well.

Sesame's clinicians handle prior authorization paperwork as part of standard practice — that's one of the practical advantages of going through a telehealth platform rather than trying to navigate insurance directly. For patients whose plans do cover oral GLP-1 therapy, total monthly cost can come down to $25–$100 with manufacturer savings cards applied on top of insurance.

What Sesame does not offer

This section is worth dwelling on because it's the opposite of the pitch you'll get from most oral GLP-1 telehealth platforms:

• No compounded semaglutide in any format (drops, tablets, ODTs, lozenges, gummies)
• No compounded tirzepatide in any format
• No "oral tirzepatide" drops or similar products
• No bundled pricing that combines brand and compounded products
• No programs that "start you on" compounded and "transition you to" brand

If you come to Sesame wanting any of the above, they won't sell it to you. This is either the platform's greatest strength or its biggest limitation, depending on what you're looking for. For patients who specifically want FDA-approved medications with a clean regulatory story, it's the feature. For patients who want to experiment with cheaper compounded alternatives, Sesame isn't the right platform — you'd want a compounder like MangoRx, SHED, or Care Bare Rx instead.

The restriction is the value proposition. Sesame doesn't have a compounded product because they don't want one in their catalog.

The telehealth experience

Sesame's signup and visit experience is among the more polished we've encountered. The platform lets you browse clinicians, read bios, and see visit ratings before booking — closer to a traditional appointment-booking system than the questionnaire-first flow that most weight-loss telehealth platforms use. Visits are conducted by video with licensed clinicians (MDs, DOs, NPs, PAs) operating within their scope of practice.

For follow-up visits after your initial consult, you can usually book shorter, lower-cost appointments for dose escalation, medication management, and prescription refills. The company reports that many patients maintain their oral GLP-1 therapy at around $250–$350 per month all-in (medication plus ongoing visits), depending on starter vs maintenance dosing and insurance status.

Pros and cons

Who Sesame Care is best for

• Patients starting from scratch who want the cleanest available regulatory path
• Patients with commercial insurance that covers oral GLP-1s — Sesame will handle the prior authorization
• Patients with type 2 diabetes seeking weight loss through Rybelsus (better insurance coverage)
• Patients who can accommodate the fasting window (empty stomach, 30-minute wait before eating) that all oral semaglutide products require
• Patients who've had concerns about compounding pharmacy quality or the regulatory environment for compounded products

Editorial verdict

Sesame Care is the best available telehealth path to FDA-approved oral GLP-1 medications in April 2026. The combination of Novo Nordisk Recognized Care Provider status, NovoCare Direct pricing access, clean regulatory history, and visit-based telehealth model adds up to a platform that's hard to beat for the specific use case of getting the Wegovy pill or Rybelsus through telehealth.

The platform's intentional limits — no compounded products, no format variety, no bundled creativity — are the feature, not the bug. If you want FDA-approved oral GLP-1, Sesame is the best option. If you want anything else, you'd want a different provider.